Generating deeper and more durable BCMA CAR T cell responses in Multiple Myeloma through non-viral knockin/knockout multiplexed genome engineering
Grant Award Details
Grant Type:
Grant Number:
DISC2-13051
Investigator(s):
Disease Focus:
Human Stem Cell Use:
Award Value:
$1,463,368
Status:
Active
Progress Reports
Reporting Period:
Year 2
Grant Application Details
Application Title:
Generating deeper and more durable BCMA CAR T cell responses in Multiple Myeloma through non-viral knockin/knockout multiplexed genome engineering
Public Abstract:
Research Objective
We will use integrated gene editing techniques to develop a new CAR-T cell therapy for multiple myeloma treatment
Impact
Develop an improved CAR-T cell therapy for patients with refractory multiple myeloma and a new manufacturing strategy that circumvents the costs and inefficiencies of viral production.
Major Proposed Activities
We will use integrated gene editing techniques to develop a new CAR-T cell therapy for multiple myeloma treatment
Impact
Develop an improved CAR-T cell therapy for patients with refractory multiple myeloma and a new manufacturing strategy that circumvents the costs and inefficiencies of viral production.
Major Proposed Activities
- Establish and optimize a CRISPR Cas9 editing strategy to generate combined non-viral TRAC-targeted BCMA CAR-T cells with RASA2 ablation.
- Evaluate key functional characteristics of TRAC-targeted BMCA CAR T cells with RASA2 ablation in vitro.
- In vivo evaluation of RASA2 KO TRAC-targeted BCMA CAR-T cells in immunocompromised mice xenografted with multiple myeloma.
Statement of Benefit to California:
Multiple Myeloma (MM) is the second most common blood cancer, and currently there is no cure. The MM team at UCSF, home to the Grand Multiple Myeloma Translational Initiative, provides cutting edge care and offers hope through clinical trials to many Californians with refractory MM. We aim to develop an improved CAR-T cell therapy that will demonstrate deeper and more enduring MM responses in an early phase clinical trial here at UCSF, and ultimately will become accessible to all patients.